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ates the financial impact of apixaban introduction by comparing expected 1,2, and 
3 years costs in hypothetical scenarios: with and without apixaban. Italian NVAF 
patient population estimation is based on official apixaban reimbursement criteria, 
applying the characteristics of the trial population to national epidemiologic data. 
Sensitivity analysis is performed on an alternative non-experimental population of 
NVAF patients. Results: Among available NOACs, apixaban is expected to be the 
least expensive at 1,2, and 3 years in an estimated patient population of 364,000 
Italian patients, allowing for savings of over 5 million € by the third year. Results of 
the simulation run on an alternative non-experimental population of NVAF patients 
yields comparable estimates. Exclusive use of apixaban for three years in the identi-
fied population would allow for savings of € 8,832,500, € 14,446,551 and € 27,282,998 
when compared with dabigatran (110 mg), dabigatran (150 mg) and rivaroxaban, 
respectively. ConClusions: The different safety and effectiveness profiles of the 
available NOACs emerging from the adjusted indirect comparison indicate that the 
introduction of apixaban could improve health care expenditure control while main-
taining or increasing therapeutic appropriateness in the Italian NVAF population.
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The BudgeT ImPaCT Of New geNeraTION CT SCaNNerS fOr dIffICulT-TO-
Image, lOw-rISk PaTIeNTS wITh SuSPeCTed Cad
Shields G.E., Chapman A.M.
BresMed, Sheffield, UK
objeCtives: The National Institute of Health and Care Excellence (NICE) issued 
diagnostic guidance on new generation computed tomography (CT) scanners rec-
ommending them as an option for the first-line imaging of coronary arteries in 
patients with suspected low-risk coronary artery disease (CAD) in whom imaging 
with old generation scanners is difficult (e.g. obese patients). The capital investment 
for a new generation scanner is considerably more than a standard scanner, which 
could hamper implementation. Based on the NICE guidance, a model was designed 
for use as a planning tool for rapid access chest pain clinics (RACPCs) looking to 
replace their current scanner with a new generation scanner. Methods: An Excel® 
model was developed to estimate up to a 10-year impact of acquiring a new genera-
tion scanner. It was assumed that under standard care low-risk, difficult-to-image 
patients would be referred for a diagnostic invasive coronary angiography (ICA). 
Under the new diagnostic pathway these patients can be scanned with a new gener-
ation scanner. Whenever possible the NICE guidance was used to guide assumptions 
and populate default values. Results: The model estimates that for each difficult-
to-image patient a new generation scanner has the potential to save approximately 
£946.62 in diagnostic costs. Considering the capital investment required, a RACPC 
looking to replace their standard scanner and considering implementing a new 
generation CT scanner only need 53 difficult-to-image patients per year to see a 
positive return on investment over a 10-year period. ConClusions: The model is 
likely to be conservative as it focuses on difficult-to-image patients only, yet the 
scanner is available for all patients who will likely benefit from the better sensitivity 
and specificity associated with the new scanners. However, it highlights that even 
a low number of these difficult-to-image patients will result in a positive return on 
investment over the expected life-time of the scanner.
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SImVaSTaTIN PluS feNOfIBraTe aS a fIxed dOSe COmBINaTION IN The 
TreaTmeNT Of mIxed dySlIPIdemIa IN greeCe: BudgeT ImPaCT aNalySIS
Relakis J.1, Kourlaba G.2, Maniadakis N.1
1National School of Public Health, Athens, Greece, 2National and Kapodistrian University of 
Athens School of Medicine, Athens, Greece
objeCtives: To evaluate the affordability of switching patients already treated with 
the multi-pill therapy of simvastatin and fenofibrate to the first simvastatin and 
fenofibrate fixed dosed combinations (FDC) product, for the management of mixed 
dyslipidemia in the Greek health care setting. Methods: A budget impact model 
was locally adapted. The analysis was conducted from a third-party payer perspec-
tive over a time horizon of 3 years. The population with mixed dyslipidemia in 
Greece, the market shares of available treatments and the corresponding drug acqui-
sition costs were combined to estimate the total budgetary impact that will result 
from the penetration of FDC in the Greek market. Data on population with mixed 
dyslipidemia were derived from the National Statistical Service and published litera-
ture. Estimates of the current and future market shares were obtained from Abbott 
Hellas market research. Drug acquisition costs were calculated using the latest 
price bulletin issued and the corresponding reimbursement prices. Reimbursement 
prices were reduced by the patient’s relevant co-payment and relative rebates. Since 
market prices for the FDC are not available yet in Greece, estimated retail prices 
provided by Abbott Hellas were considered [FDC 20/145: € 13.70 (€ 12.22-16.27) and 
FDC 40/145: € 16.71 (€ 15.22-19.23)]. Results: Savings in pharmaceutical reimburse-
ment on year 1 were estimated at 146,974 (€ 181,084-€ 88,503) decreasing the relevant 
cost by 5.87% (7.23%-3.53%). On year 2, savings of € 250,544 (€ 322,536-€ 136,474) were 
attributed to the penetration of FDC, lowering the budget by 9.93% (12.78%-5.41%). 
On the 3rdyear, savings were estimated at € 403,405 (€ 509,489-€ 221,565) reducing 
spending by 15.82% (19.98%-8.69%). On average, over the 3-year time horizon of the 
analysis, the addition of FDC was found to decrease reimbursement costs by 10.54% 
(13.33%-5.88%) generating savings of € 266,974 (337,703€ -€ 148,147). ConClusions: 
The introduction of FDC reimbursement will result in a predictable budget impact 
which is expected to decrease the relevant pharmaceutical cost for national health 
insurance.
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BudgeT ImPaCT aNalySIS Of BOTulINum TOxIN a TheraPy fOr uPPer lImB 
SPaSTICITy IN germaNy
Zoellner Y.F.1, Gerwe M.2, Richter M.2
1Hamburg University of Applied Sciences, Hamburg, Germany, 2Ipsen Pharma, Ettlingen, Germany
objeCtives: Upper limb spasticity (ULS) secondary to stroke has a considerable 
patient and caregiver burden, particularly with regards to pain, activities of daily 
quitting smoking. Cost of 5-year reimbursement varenicline was estimated to 
be € 63.0 millions, while smoking cessation avoided costs reached € 99.9 millions, 
which compared with € 21.1 millions savings in the not-reimbursed scenario: a net 
incremental cost-saving of € 15.9 millions. Savings were observed since 3rd year of 
modelling. ConClusions: The BI of the reimbursement of varenicline in smoking 
cessation is a cost-effective health policy in the Spanish NHS, and could produce 
cost-savings since the 3rd year of implementation.
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objeCtives: The aim of this study was to calculate and compare public payer and 
patients’ costs of hypertensive treatment with indapamide 1.5 mg and amlodipine 
5 mg or 10 mg single-pill combination (SPC) and free combination (FC), in the Polish 
setting. Methods: The analysis compared two scenarios: existing and new. The 
existing one assumed treatment with FC of indapamide 1.5 mg and amlodipine 5 
mg or 10 mg. The new one also included treatment with SPC of indapamide 1.5 mg 
+amlodipine 5/10 mg. Population and market shares were estimated on the basis of 
published reimbursement data, experts’ opinion and validated with available epide-
miological data. Cost data were analysed from the public payer perspective (National 
Health Fund) and from patient perspective, in a three-year horizon. SPC cost is based 
on average pharmacy price reported in April 2014 (18.13PLN and 19.75PLN respec-
tively for 1.5+5mg and 1.5+10mg /30 tabs); 30% patient copayment was assumed. 
The cost of FC was calculated as an average cost of reimbursed indapamide and 
amlodipine products in corresponding doses. All costs present 2014 values, and are 
expressed in Polish zloty (PLN). Average monthly exchange rate of May 2014 was 
applied (1EUR= 4.1790PLN). Difference in clinical effectiveness between SPC and FC 
was also included, in the form of cardiovascular events risk. Results: Introduction 
of indapamide/amlodipine SPC on the reimbursement list next to FC brought savings 
from public payer perspective and from patient perspective amounting to: 509,255PLN 
(121,860EUR) and 5,893,941PLN (1,410,371EUR) in first year, 689,239PLN (164,929EUR) 
and 7,833,005PLN (1,874,373EUR) in second year, 725,965PLN (173,717EUR) and 
8,328,480PLN (1,992,936EUR) in third year. Additionally it resulted in avoidance of 
808 cardiovascular events in the three-year horizon. ConClusions: Treatment with 
indapamide/amlodipine SPC in comparison to FC generates significant savings both 
from the public payer perspective and from patient perspective in contemporary 
Polish setting, and reduces cardiovascular events.
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mOdelINg The ImPaCT Of a dIgITal healTh feedBaCk SySTem IN 
uNCONTrOlled hyPerTeNSIVe PaTIeNTS
Kim Y.A., Virdhi N., Raja P., DiCarlo L.
Proteus Digital Health, Redwood City, CA, USA
objeCtives: Despite the availability of numerous therapeutic agents and manage-
ment tools, half of all hypertensive patients do not have their blood pressure (BP) 
at goal. A model was developed to estimate the incremental costs of uncontrolled 
vs. controlled hypertension and the impact of shifting patients to controlled sta-
tus via a unique digital health feedback system. This Proteus system utilizes an 
Ingestible Sensor to determine medication-taking patterns, and a wearable 7-day 
sensor in the form of an adhesive patch to collect physiological and behavioral 
metrics such as heart rate, step count, and patterns of activity and rest, providing 
a means of determining non-response vs. non-adherence to prescribed medica-
tions and recommendations for daily routine. Methods: The additional costs of 
outpatient services, monitoring, and cardiovascular complications were calculated 
for uncontrolled vs. controlled hypertensive patients from a US plan perspective for 
a 1 year time horizon. The clinical and utilization assumptions were derived from 
the literature and expert opinion, and costs were derived from the Medicare Fee 
Schedule and AHRQ databases. The impact of the Proteus system on BP control was 
based on a real-world study evaluating this technology in 164 patients with a history 
of uncontrolled hypertension. Results: In a health plan of 1 million members, 7.9% 
(78,656) were uncontrolled hypertensive patients receiving care who were eligible for 
the Proteus system. The direct annual medical costs of uncontrolled hypertension 
were estimated to be $60.9 million over the costs for controlled disease. The Proteus 
system was estimated to result in $7.3-18.3 million in savings ($328-$717 per BP at 
goal), and lead to a 3-9% reduction in the number of coronary artery disease and 
stroke events in one year. ConClusions: Even in the short-term, a digital health 
feedback system appears to provide an effective way to mitigate the substantial 
costs of uncontrolled hypertension.
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BudgeT ImPaCT aNalySIS Of aPIxaBaN VerSuS OTher NOaCS fOr The 
PreVeNTION Of STrOke IN ITalIaN NON-ValVular aTrIal fIBrIllaTION 
PaTIeNTS
Pradelli L.1, Calandriello M.2, Di Virgilio R.3, Bellone M.1, Tubaro M.4
1AdRes HE&OR, Turin, Italy, 2HE OR Unit - Bristol-Myers Squibb S. r. l., Rome, Italy, 3Pfizer 
Pharmaceuticals, Rome, Italy, 4San Filippo Neri Hospital, Rome, Italy
objeCtives: This study aims to perform a budget impact analysis of the use of three 
available novel oral anticoagulant agents (NOACs) for preventing thromboembolic 
events in Italian patients with non-valvular atrial fibrillation (NVAF). Methods: 
Estimated Italian population of patients is run through a decision tree/Markov 
model simulating their treatment with the available therapeutic options: dabigatran 
at two dose levels (110 mg/bid for the over 80 years old, 150 mg/bid for younger NVAF 
patients), rivaroxaban, and apixaban. Effectiveness estimates derive from an adjusted 
indirect treatment comparison using warfarin as link. Epidemiological data and unit 
costs are collected from Italian published sources. The budget impact analysis evalu-
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of the study is that the safety data were obtained from clinical trials rather than 
actual clinical practice with these drugs.
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eSTImaTINg The Value Of CaNgrelOr frOm elImINaTINg PrelOadINg IN 
COrONary arTery ByPaSS grafT (CaBg) PaTIeNTS
Bay C., Cyr P.L., Jensen I.
ICON plc, Cambridge, MA, USA
objeCtives: 2011 AHA and 2012 ESC guidelines recommend antiplatelet therapy 
at presentation for suspected ACS patients. For CABG patients (approximately 10% 
of ACS presentations) this strategy creates a dilemma: delay CABG to washout anti-
platelet therapy or perform surgery and risk bleeding. Bridging strategies have been 
proposed using GPIs. Cangrelor, a novel reversible, IV P2Y12 inhibitor with rapid 
onset/offset, demonstrated in the CHAMPION PHOENIX trial a reduction in ischemic 
events vs. clopidogrel in patients undergoing PCI. Adoption of cangrelor for angiog-
raphy in ACS patients eliminates the need to washout an oral P2Y12inhibitor in case 
of unanticipated CABG. The aim of our analysis was to quantify the annual value of 
this pathway change to a US hospital. Methods: A decision analytic model based 
on the current CABG patient pathway was developed to quantify the value of a 
reduction in bridging by adopting cangrelor from a US hospital perspective. Premier 
hospital database informed the timing of CABG after washout; demographics, drug-
mix, LOS, blood product utilization, and hospital ward costs. Ischemic event rates 
and costs were informed by published sources. Drug costs were 2014 wholesale 
acquisition costs. Cangrelor cost was set to $0. Results: For a hypothetical US 
hospital treating 195 CABG patients/year (patient mix: 4% STE-ACS, 26% NSTE-ACS, 
70% SA), shifting away from bridging with GPI by adopting cangrelor resulted in a 
total annual cost reduction of $120,000. Total costs in the base-case are estimated 
to be $2.95MM vs. the scenario case of $2.83MM. Cost savings were derived from 
eliminating GPI utilization, lowering washout drug costs and reducing hospitaliza-
tion days. ConClusions: Removal of the need to washout oral antiplatelet therapy 
prior to CABG through adoption of cangrelor is estimated to deliver a clinical value 
of ~$615/CABG patient with fewer total days spent hospitalized.
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Sánchez Chorro J.L.2, Hidalgo A.3
1Servicio Extremeño de Salud, Mérida, Spain, 2Extremadura Health System, Mérida, Spain, 
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objeCtives: To analyse the budgetary impact (BI) of the introduction of NOAC 
in patients with NVAF compared to warfarin treatment scenario (DC) from the 
perspective of the public health system of Extremadura (PHSE). Methods: 
A budget impact study was performed during 2013. It was based on anticoagulant 
therapy (AO) on patients with NVAF. The data came from the electronic clinical his-
tory called JARA®. Pharmaceutical costs associated to the control and monitoring 
of patients with DC were included. Specifically those related to the incidence of 
stroke (CVA), gastrointestinal haemorrhage (HG), intracranial haemorrhage (ICH) 
and acute myocardial infarction (AMI) as the RE-LY, ROCKET and ARISTOTLE trials. 
For DC, there were taken into account the best and worst scenario. The pharmaceu-
tical cost considered was the sum of the official price and the VAT. To other public 
health costs, official prices from the PHSE and the Spanish National Health Care 
System were considered. Results: Treatment distribution among patients was 
92.63% DC; 4.02% Dabigatran (DAB); 3.07% rivaroxaban (RIV) and 0.28% Apixaban 
(APX). The total expenditure for the AO patients with VKA in the best scenario is 
€ 3,036,604.28 (average cost per patient: € 342.11, CI 95%: 341.89 - 342.34) and the 
worst would be € 3,727,169 (€ 419.92, CI 95%: 419.70 - 420.15). For NOAC the results 
are € 572,515.39 (€ 810.93, CI 95%I: 786.71 - 835.16). NOAC represent the 71.44% of the 
pharmaceutical expenditure (PE), the 23.47% of PE’s control and monitoring of DC 
and the 15.86% of the total expenditure from AO patients with NVAF, in the best sce-
nario. ConClusions: The market access of NOAC has been modest and similar to 
the rest of Spain. AVK alternative has the lowest average cost per patient. Limitation: 
safety data has been obtained from clinical trials instead of using clinical practice.
PCV47
The mOVe TOwardS full ImPlemeNTaTION Of The NICe guIdelINeS fOr 
STrOke PreVeNTION IN aTrIal fIBrIllaTION: The POTeNTIal COST aNd 
ClINICal ImPaCT
Shields G.E., Chapman A.M.
BresMed, Sheffield, UK
objeCtives: Updated treatment guidelines for atrial fibrillation (AF) have been 
released by the National Institute for Health and Care Excellence (NICE) in the 
United Kingdom and highlight a current shortfall in the prescribing of anticoagu-
lants to patients with AF despite the importance of stroke prevention. A model 
was designed for use as a planning tool for Clinical Commissioning Groups (CCGs) 
looking to budget for the future move towards full implementation of the NICE 
guidelines. Methods: An Excel model was developed to estimate the 5-year 
impact of gradually treating all eligible AF patients who are currently not being 
prescribed anticoagulants, both in terms of the effect on clinical outcomes (strokes, 
major bleeds and mortality) and the financial impact associated with treating more 
patients. Assumptions had to be made in order to simplify the model and populate 
default values. Risks of clinical outcomes were taken from a literature search. Costs 
were taken from published national sources. Results: In an average sized CCG 
(population of 226,000) the model estimated that in order to gradually treat the full 
eligible AF patient population, an additional budget of £103,899 will be required in 
Year 1 to treat an additional 248 patients, rising to £791,076 in Year 5 to treat an 
additional 1,889 patients. Cumulatively over the 5-year timeframe this could lead 
to the prevention of 8 ischemic strokes and 3 deaths, as well as an increase of 2 
haemorrhagic strokes and 8 bleeds. ConClusions: The clinical benefits of appro-
living and mobility. Botulinum neurotoxin-A (BoNT-A) injections are effective in 
treating ULS. We aimed to calculate annual BoNT-A treatment cost of ULS on a 
per-patient basis, and the expected overall annual budget impact of BoNT-A treat-
ment in Germany using static and dynamic market share scenarios. Methods: 
A budget impact model for BoNT-A use, adopting a German health care system 
perspective, was developed. Two market-share scenarios were modelled over 5 years. 
While the static scenario assumed current market shares (abobotulinumtoxinA, 
36%; onabotulinumtoxinA, 26%; incobotulinumtoxinA, 38%) to remain constant over 
time, the dynamic scenario assumed market share of abobotulinumtoxinA to rise 
up to 76% across 5 years. Epidemiologic data inputs were sourced from the most 
recently published literature, unit costs for BoNT-As from the Lauertaxe (pharmacy 
purchase price [PPP] level), and market share assumptions from IMS Health (Market 
Sizing). Equivalence of the 3 BoNTAs in terms of efficacy and safety is assumed and 
therefore no differential use of medical services or other goods. Results: Annual 
BoNT-A drug costs per ULS patient were 3 463€ , 5 603€ , and 5 410€ , respectively, 
with prescribing patterns following SmPC recommendations for abobotulinum-
toxinA, onabotulinumtoxinA, and incobotulinumtoxinA. The total drug costs were 
decreased by between 1 231 861€ (-4%) in year 2 and 5 133 684€ (-17%) in year 5 by 
shifting the market share to abobotulinumtoxinA. Sensitivity analyses showed that 
the number of patients treated with BoNT-As, time to re-injection, and dose per 
injection were the most influential parameters on budget impact, impacting both 
drug acquisition costs and physician visits. ConClusions: Increased use of abo-
botulinumtoxinA compared with incobotulinumtoxinA and onabotulinumtoxinA 
for ULS in Germany could potentially reduce the total cost of treatment.
PCV43
reNal deNerVaTION wITh The SymPlICITy CaTheTer SySTem fOr 
TreaTmeNT-reSISTaNT hyPerTeNSION: a BudgeT ImPaCT aNalySIS
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objeCtives: Renal denervation (RDN) is a new treatment option for patients with 
uncontrolled resistant hypertension. Studies have shown RDN to have a potential 
reduction in systolic blood pressure and therefore reduce risk for different cerebro-
cardiovascular disease (stroke, ischemic heart disease, heart failure, etc.). The aim is 
to assess the economic impact of renal denervation in resistant hypertensive patients 
based on the potential clinical benefit demonstrated in literature. Methods: 
A budget impact model was developed to quantify RDN-related cost-savings accom-
plished through lower rate of cerebro-cardiovascular events compared with the 
medical treatment cohort (with 3+ anti-hypertensive medications including a diu-
retic). The model was developed from the Italian National Healthcare Service (NHS) 
perspective with a 10-year time horizon. The risk of events was calculated using 
different multivariate equations. A literature review was carried out to collect the 
treatment costs for both acute and chronic phase of hypertension-related events. 
The cost of RDN procedure was approximated to the related DRG tariff. Results: 
Renal denervation, considering the blood pressure reduction observed after pro-
cedure, substantially reduces cerebro-cardiovascular event probabilities by 30% if 
compared to the medical treatment cohort. Assuming a yearly 2% RDN adoption 
rate, approximately 2,000 events would be avoided in 10 years allowing total savings 
up to 9 Million euro. The higher cost of new technology was offset from potential 
saving associated to the avoided events. Compared to the total costs associated 
to the medical treatment cohort in 10 years the overall expenditure for RDN was 
greater than 0.8%. The annual incremental cost for patients treated with surgical 
approach was estimated at 16 euro per patient. ConClusions:  The economic 
impact of hypertension-related complications is significant in the Italian setting. 
Consequently the potential savings according to the NHS perspective derived from 
the implementation of strategies aimed at improving the level of hypertension 
should be considered.
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objeCtives: To estimate the costs associated with the use of dabigatran (DB) vs. 
dicoumarins (DC) in non-valvular atrial fibrillation (NVAF) from the perspective 
of the Extremadura Public Health System (EPHS) in 2013. Methods: A budget 
impact study of anticoagulant therapy (AT) with DB and DC in patients with NVAF 
was carried out during 2013. The data were processed using the JARA® electronic 
record application. Pharmaceutical costs and costs associated with patient follow-
up and monitoring were included. Costs relating to incidence of stroke, gastroin-
testinal bleeding, intracranial haemorrhage and acute myocardial infarction were 
also included based on RE-LY clinical trials. For pharmaceutical cost RRP + VAT of 
the medicinal products was used, and other health care costs were based on the 
public prices of the EPHS and the National Health System. Results: Three hun-
dred eighty-five patients were treated with DB (4.01 %) and 8876 with DC (92.63%). 
Mean age was 77 (95 % CI: 76.82-77.19). Total expenditure for AT with AVK for the 
best case scenario would be € 3,036,604.28 (mean cost per patient: € 342.11; 95% 
CI: 341.80-342.34) and the worst case € 3,727,169.83 (€ 419.92; 95% CI: 419.70-419.15) 
and for DB € 318,077.15 (mean expenditure: € 826.27; 95% CI: 796.81-855.57). For a 
DB market penetration of 50%, expenditure on anticoagulation of these patients 
would be € 3,958,659.57 while for 75% it would be € 5,937,989.36. ConClusions: 
Dabigatran is a more costly option than classic treatment with DC. In 2013 this drug’s 
market penetration was limited and was closer to other estimates. Estimated mean 
cost per patient for DCs is similar to the estimates of other communities (Basque 
Country: € 300-700 and the Valencian Community: € 300) and are somewhat lower 
for DB (Basque Country: € 1,197 and the Valencian Community: € 1,350). A limitation 
